

Special Issue

Neuromuscular Disorders: Clinical Treatment and Molecular Genetics

Message from the Guest Editors

Due to the clinical studies and neuropathology of neuromuscular disorders, the transition to understanding genes paves the way for new molecular treatments. The translational neurogenetics of neuromuscular disorders and its evolution, historically, were great challenges, but the identification of new/novel genes may change our treatment directions. This Special Issue will focus on how our clinical acumen can be aided by genetics and for which molecular treatments it will be important to proceed with. The Special Issue also intends to highlight the merger of our clinical phenotyping with genotyping as we confront our neuromuscular patients. We welcome submissions on:

- Phenotype-genotype correlates in hereditary myopathies and neuropathies.
- How genetics impacted our clinical pathways for care of our neuromuscular patients.

Guest Editors

Prof. Dr. Raymond L. Rosales

Research Center for Health Sciences, University of Santo Tomas and Hospital, Manila 1008, Philippines

Prof. Dr. Satish V Khadilkar

Dean and Professor and Head, Department of Neurology, BHIMS, Mumbai 400020, India

Deadline for manuscript submissions

closed (15 May 2023)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/142973

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))